Colistin therapy for microbiologically documented multidrug-resistant Gram-negative bacterial infections: a retrospective cohort study of 258 patients

Falagas, Matthew E.; Rafailidis, Petros I.; Ioannidou, Elda; Alexiou, Vangelis G.; Matthaiou, Dimitrios K.; Karageorgopoulos, Drosos E.; Kapaskelis, Anastasios; Nikita, Dimitra; Michalopoulos, Argyris

doi:10.1016/j.ijantimicag.2009.10.005

Cited by 278 publications

(250 citation statements)

References 15 publications

Supporting

Mentioning

209

Contrasting

Unclassified

Order By: Relevance

“…1 Resistance also affects the choice of 'targeted' therapy once a pathogen has been isolated, identified and subjected to susceptibility testing. In some cases, treatment options are very limited, and the emergence and proliferation of multiresistant Gram-negative organisms -both Enterobacteriaceae and non-fermenters -is forcing the renewed use of old antibiotics, notably colistin/polymyxin B and fosfomycin [2][3][4][5][6] and of tigecycline. Similarly, the emergence of Gram-positive pathogens resistant to β-lactams and glycopeptides is leading to the use of linezolid, daptomycin and tigecycline in hematology patients.…”

Section: Introductionmentioning

confidence: 99%

“…3,45,47,63 A recently-published prospective observational study in intensive care unit patients with severe infections due to Gram-negative bacteria susceptible only to colistin recorded clinical cures in 82% of cases when colistin was administered as a 9-million-unit loading dose followed by 9 million units daily, given in two doses, as maintenance therapy. 64 Combination of colistin/polymyxin B with other agents to which the bacteria show in vitro sensitivity is strongly encouraged (e.g.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Targeted therapy against multi-resistant bacteria in leukemic and hematopoietic stem cell transplant recipients: guidelines of the 4th European Conference on Infections in Leukemia (ECIL-4, 2011)

et al. 2013

View full text Add to dashboard Cite

The detection of multi-resistant bacterial pathogens, particularly those to carbapenemases, in leukemic and stem cell transplant patients forces the use of old or non-conventional agents as the only remaining treatment options. These include colistin/polymyxin B, tigecycline, fosfomycin and various anti-gram-positive agents. Data on the use of these agents in leukemic patients are scanty, with only linezolid subjected to formal trials. The Expert Group of the 4 th European Conference on Infections in Leukemia has developed guidelines for their use in these patient populations. Targeted therapy should be based on (i) in vitro susceptibility data, (ii) knowledge of the best treatment option against the particular species or phenotype of bacteria, (iii) pharmacokinetic/pharmacodynamic data, and (iv) careful assessment of the risk-benefit balance. For infections due to resistant Gram-negative bacteria, these agents should be preferably used in combination with other agents that remain active in vitro, because of suboptimal efficacy (e.g., tigecycline) and the risk of emergent resistance (e.g., fosfomycin). The paucity of new antibacterial drugs in the near future should lead us to limit the use of these drugs to situations where no alternative exists. ABSTRACT © F e r r a t a S t o r t i F o u n d a t i o n 2 0 1 3organizing committee and experts were solicited to form the working group. The group reviewed the published English-language literature and prepared proposals on treatment options for infections due to resistant bacteria. Papers for review were sought using PubMed with the terms "linezolid", "daptomycin", "quinupristin/ dalfopristin", "colistin or polymyxin", "tigecycline", "fosfomycin", "telavancin", "ceftaroline" AND "stem cell transplantation or bone marrow transplant or leukemia or hematological malignancy or cancer". References cited in the articles identified were also considered. In respect of 'Duration of therapy', the main search terms used were "antibiotic therapy"; "stem cell transplantation or bone marrow transplantation or hematological malignancy or cancer"; "febrile neutropenia" and "duration therapy", "discontinuation antibiotics" and "microbiologically documented infection". Definitions of resistanceA bacterial isolate was considered non-susceptible if it was categorized resistant, intermediate or non-susceptible when using clinical breakpoints of the European Committee on Antimicrobial Susceptibility Testing (EUCAST), Clinical and Laboratory Standards Institute (CLSI) or the US Food and Drug Administration (FDA). Definitions of 'MDR' vary among authors and usually presume resistance to at least two antibiotics used in empiric therapy (3 rd 4 th -generation cephalosporins, carbapenems or piperacillin/tazobactam) or resistance to at least three of the following antibiotic classes: antipseudomonal penicillins, cephalosporins, carbapenems, aminoglycosides and fluoroquinolones. [11][12][13][14][15] According to the recent definition of the European Centre for Disease Prevention and Control...

show abstract

Section: Introductionmentioning

confidence: 99%

mentioning

confidence: 99%

Targeted therapy against multi-resistant bacteria in leukemic and hematopoietic stem cell transplant recipients: guidelines of the 4th European Conference on Infections in Leukemia (ECIL-4, 2011)

et al. 2013

View full text Add to dashboard Cite

show abstract

“…During the last decade, there has been a resurgence in the use of old antibiotics, such as polymyxins, with improvements in dosing, different synergistic antimicrobial combinations and novel pharmaceutical formulations that have made it possible to reintroduce them into clinical practice (Falagas et al, 2010). This was in response to the few therapeutic options that remain.…”

Section: Introductionmentioning

confidence: 99%

Transposons and integrons in colistin-resistant clones of Klebsiella pneumoniae and Acinetobacter baumannii with epidemic or sporadic behaviour

Arduino

Quiroga

Ramírez

et al. 2012

Journal of Medical Microbiology

View full text Add to dashboard Cite

“…Likewise, carbapenemase-producing strains such as Klebsiella pneumoniae carbapenemase (KPC) and New Delhi metallo-beta-lactamase producers, which are not susceptible to imipenem or other carbapenem drugs, have rapidly emerged and spread worldwide (2) (3) . Colistin and polymyxin B are among the few remaining drugs able to combat these multidrug-resistant strains and having satisfactory effi cacy in the treatment of patients infected with KPC-producing K. pneumoniae (4) . However, KPC producers also resistant to polymyxins have recently been detected (5) .…”

mentioning

confidence: 99%

Induction and nosocomial dissemination of carbapenem and polymyxin-resistant Klebsiella pneumoniae

Gaspar

Bellissimo-Rodrigues

Andrade

et al. 2015

Rev. Soc. Bras. Med. Trop.

View full text Add to dashboard Cite

Introduction:Polymyxins are antimicrobial agents capable of controlling carbapenemase-producing Klebsiella pneumoniae infection. Methods: We report a cluster of four patients colonized or infected by polymyxin-resistant and Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae. Results: Three patients were hospitalized in adjacent wards, and two were admitted to the intensive care unit. The index case maintained prolonged intestinal colonization by KPC-producing K. pneumoniae. Three patients received polymyxin B before the isolation of polymyxin-resistant K. pneumoniae. Conclusions: Colonization by KPC-producing K. pneumoniae and previous use of polymyxin B may be causally related to the development of polymyxin-resistant microorganisms.

show abstract

Colistin therapy for microbiologically documented multidrug-resistant Gram-negative bacterial infections: a retrospective cohort study of 258 patients

Cited by 278 publications

References 15 publications

Targeted therapy against multi-resistant bacteria in leukemic and hematopoietic stem cell transplant recipients: guidelines of the 4th European Conference on Infections in Leukemia (ECIL-4, 2011)

Targeted therapy against multi-resistant bacteria in leukemic and hematopoietic stem cell transplant recipients: guidelines of the 4th European Conference on Infections in Leukemia (ECIL-4, 2011)

Transposons and integrons in colistin-resistant clones of Klebsiella pneumoniae and Acinetobacter baumannii with epidemic or sporadic behaviour

Induction and nosocomial dissemination of carbapenem and polymyxin-resistant Klebsiella pneumoniae

Contact Info

Product

Resources

About